{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:12:38Z","timestamp":1778141558856,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,7]]},"DOI":"10.7759\/cureus.108406","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:32:37Z","timestamp":1778139157000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring Treatment Paradigms in Type 2 Diabetes: A Comparison of Independent and Combined Therapeutic Approaches"],"prefix":"10.7759","author":[{"given":"Kumar","family":"Sambhav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ambrish Kumar","family":"Batham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avaniben Sharadbhai","family":"Nimavat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niraj","family":"Lodha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aashish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee S","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017, 389:2239-51. 10.1016\/S0140-6736(17)30058-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022, 65:1925-66. 10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2470","article-title":"Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association's standards of medical care in diabetes clinical guideline","volume":"173","author":"Doyle-Delgado K","year":"2020","unstructured":"Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association's standards of medical care in diabetes clinical guideline. Ann Intern Med. 2020, 173:813-21. 10.7326\/M20-2470","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1690339","article-title":"Study protocol of a multicenter, randomized, non-inferiority, open-label study investigating the efficacy of a fixed-dose combination regimen of dapagliflozin\/metformin versus co-administered dual therapy based on glycemic control, satisfaction and adherence in patients with newly diagnosed type 2 diabetes mellitus","volume":"16","author":"Wang J","year":"2025","unstructured":"Wang J, Wei Y, Shi P, et al.. Study protocol of a multicenter, randomized, non-inferiority, open-label study investigating the efficacy of a fixed-dose combination regimen of dapagliflozin\/metformin versus co-administered dual therapy based on glycemic control, satisfaction and adherence in patients with newly diagnosed type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025, 16:1690339. 10.3389\/fendo.2025.1690339","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun H","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022, 183:109119. 10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01655-5","article-title":"Type 2 diabetes","volume":"400","author":"Ahmad E","year":"2022","unstructured":"Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022, 400:1803-20. 10.1016\/S0140-6736(22)01655-5","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: a review of current evidence","volume":"62","author":"Harding JL","year":"2019","unstructured":"Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019, 62:3-16. 10.1007\/s00125-018-4711-2","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia U","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, et al.. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020, 21:6275. 10.3390\/ijms21176275","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2015-133281","article-title":"Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective","volume":"92","author":"Zaccardi F","year":"2016","unstructured":"Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2016, 92:63-9. 10.1136\/postgradmedj-2015-133281","journal-title":"Postgrad Med J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/ds19-0029","article-title":"Overview of therapeutic inertia in diabetes: prevalence, causes, and consequences","volume":"33","author":"Karam SL","year":"2020","unstructured":"Karam SL, Dendy J, Polu S, Blonde L. Overview of therapeutic inertia in diabetes: prevalence, causes, and consequences. Diabetes Spectr. 2020, 33:8-15. 10.2337\/ds19-0029","journal-title":"Diabetes Spectr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani A","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al.. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017, 376:1407-18. 10.1056\/NEJMoa1608664","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown E","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021, 398:262-76. 10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dbi17-0045","article-title":"A global overview of precision medicine in type 2 diabetes","volume":"67","author":"Fitipaldi H","year":"2018","unstructured":"Fitipaldi H, McCarthy MI, Florez JC, Franks PW. A global overview of precision medicine in type 2 diabetes. Diabetes. 2018, 67:1911-22. 10.2337\/dbi17-0045","journal-title":"Diabetes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30052-4","article-title":"Precision medicine in the management of type 2 diabetes","volume":"6","author":"Gloyn AL","year":"2018","unstructured":"Gloyn AL, Drucker DJ. Precision medicine in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2018, 6:891-900. 10.1016\/S2213-8587(18)30052-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05585-2","article-title":"Interpreting global trends in type 2 diabetes complications and mortality","volume":"65","author":"Ali MK","year":"2022","unstructured":"Ali MK, Pearson-Stuttard J, Selvin E, Gregg EW. Interpreting global trends in type 2 diabetes complications and mortality. Diabetologia. 2022, 65:3-13. 10.1007\/s00125-021-05585-2","journal-title":"Diabetologia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1596127","article-title":"Global burden of diabetes mellitus 1990-2021: epidemiological trends, geospatial disparities, and risk factor dynamics","volume":"16","author":"Pan C","year":"2025","unstructured":"Pan C, Cao B, Fang H, Liu Y, Zhang S, Luo W, Wu Y. Global burden of diabetes mellitus 1990-2021: epidemiological trends, geospatial disparities, and risk factor dynamics. Front Endocrinol (Lausanne). 2025, 16:1596127. 10.3389\/fendo.2025.1596127","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.707371","article-title":"Type 2 diabetes mellitus: a pathophysiologic perspective","volume":"8","author":"Westman EC","year":"2021","unstructured":"Westman EC. Type 2 diabetes mellitus: a pathophysiologic perspective. Front Nutr. 2021, 8:707371. 10.3389\/fnut.2021.707371","journal-title":"Front Nutr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2022.03.019","article-title":"Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives","volume":"184","author":"Bhatti JS","year":"2022","unstructured":"Bhatti JS, Sehrawat A, Mishra J, et al.. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radic Biol Med. 2022, 184:114-34. 10.1016\/j.freeradbiomed.2022.03.019","journal-title":"Free Radic Biol Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen MC","year":"2018","unstructured":"Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018, 98:2133-223. 10.1152\/physrev.00063.2017","journal-title":"Physiol Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac213","article-title":"Loss of the incretin effect in type 2 diabetes: a systematic review and meta-analysis","volume":"107","author":"Grespan E","year":"2022","unstructured":"Grespan E, Guolo A, Muscelli E, Ferrannini E, Mari A. Loss of the incretin effect in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022, 107:2092-100. 10.1210\/clinem\/dgac213","journal-title":"J Clin Endocrinol Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo RA","year":"2021","unstructured":"DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021, 17:319-34. 10.1038\/s41581-021-00393-8","journal-title":"Nat Rev Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S006","article-title":"6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025. Diabetes Care. 2025, 48:S128-45. 10.2337\/dc25-S006","journal-title":"Diabetes Care"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200433","article-title":"Glycemia reduction in type 2 diabetes - glycemic outcomes","volume":"387","author":"The GRADE Study Research Group","year":"2022","unstructured":"The GRADE Study Research Group. Glycemia reduction in type 2 diabetes - glycemic outcomes. N Engl J Med. 2022, 387:1063-74. 10.1056\/NEJMoa2200433","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur NM","year":"2016","unstructured":"Maruthur NM, Tseng E, Hutfless S, et al.. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016, 164:740-51. 10.7326\/M15-2650","journal-title":"Ann Intern Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green JB","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al.. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015, 373:232-42. 10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews DR","year":"2019","unstructured":"Matthews DR, Pald\u00e1nius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019, 394:1519-29. 10.1016\/S0140-6736(19)32131-2","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00926-7","article-title":"Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes","volume":"11","author":"Matthews D","year":"2020","unstructured":"Matthews D, Del Prato S, Mohan V, et al.. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020, 11:2465-76. 10.1007\/s13300-020-00926-7","journal-title":"Diabetes Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen BL","year":"2024","unstructured":"Neuen BL, Fletcher RA, Heath L, et al.. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation. 2024, 150:1781-90. 10.1161\/CIRCULATIONAHA.124.071689","journal-title":"Circulation"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06565-6","article-title":"Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies","volume":"69","author":"Colombijn JM","year":"2026","unstructured":"Colombijn JM, de Leijer JF, Visseren FL, et al.. Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. Diabetologia. 2026, 69:36-49. 10.1007\/s00125-025-06565-6","journal-title":"Diabetologia"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen BL","year":"2024","unstructured":"Neuen BL, Heerspink HJ, Vart P, et al.. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024, 149:450-62. 10.1161\/CIRCULATIONAHA.123.067584","journal-title":"Circulation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-025-05455-4","article-title":"SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Ahmed AA","year":"2025","unstructured":"Ahmed AA, Ahmed OA, Ahmed RA, et al.. SGLT2 inhibitors versus GLP-1 receptor agonists for major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2025, 26:88. 10.1186\/s12872-025-05455-4","journal-title":"BMC Cardiovasc Disord"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-025-10523-0","article-title":"The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis","volume":"30","author":"Siddiqui HF","year":"2025","unstructured":"Siddiqui HF, Waqas SA, Batool RM, et al.. The effect of GLP-1 receptor agonists on cardiac remodeling in heart failure patients with preserved and reduced ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2025, 30:991-1004. 10.1007\/s10741-025-10523-0","journal-title":"Heart Fail Rev"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1605746","article-title":"A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review","volume":"16","author":"Aristiz\u00e1bal-Colorado D","year":"2025","unstructured":"Aristiz\u00e1bal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, et al.. A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review. Front Endocrinol (Lausanne). 2025, 16:1605746. 10.3389\/fendo.2025.1605746","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02900-8","article-title":"Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","volume":"24","author":"Shokravi A","year":"2025","unstructured":"Shokravi A, Seth J, Mancini GB. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. Cardiovasc Diabetol. 2025, 24:370. 10.1186\/s12933-025-02900-8","journal-title":"Cardiovasc Diabetol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05782-7","article-title":"Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time","volume":"65","author":"Griffin S","year":"2022","unstructured":"Griffin S. Diabetes precision medicine: plenty of potential, pitfalls and perils but not yet ready for prime time. Diabetologia. 2022, 65:1913-21. 10.1007\/s00125-022-05782-7","journal-title":"Diabetologia"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.273540","article-title":"Precision medicine in obesity and type 2 diabetes: the relevance of early-life exposures","volume":"64","author":"Estampador AC","year":"2018","unstructured":"Estampador AC, Franks PW. Precision medicine in obesity and type 2 diabetes: the relevance of early-life exposures. Clin Chem. 2018, 64:130-41. 10.1373\/clinchem.2017.273540","journal-title":"Clin Chem"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01790-7","article-title":"Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes","volume":"28","author":"Nair AT","year":"2022","unstructured":"Nair AT, Wesolowska-Andersen A, Brorsson C, et al.. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med. 2022, 28:982-8. 10.1038\/s41591-022-01790-7","journal-title":"Nat Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0222","article-title":"Cardiovascular disease and risk management: review of the American Diabetes Association standards of medical care in diabetes 2018","volume":"168","author":"Chamberlain JJ","year":"2018","unstructured":"Chamberlain JJ, Johnson EL, Leal S, Rhinehart AS, Shubrook JH, Peterson L. Cardiovascular disease and risk management: review of the American Diabetes Association standards of medical care in diabetes 2018. Ann Intern Med. 2018, 168:640-50. 10.7326\/M18-0222","journal-title":"Ann Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30181-X","article-title":"Diabetes in sub-Saharan Africa: from clinical care to health policy","volume":"5","author":"Atun R","year":"2017","unstructured":"Atun R, Davies JI, Gale EAM, et al.. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol. 2017, 5:622-67. 10.1016\/S2213-8587(17)30181-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0116","article-title":"Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set","volume":"41","author":"Pantalone KM","year":"2018","unstructured":"Pantalone KM, Misra-Hebert AD, Hobbs TM, et al.. Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care. 2018, 41:e113-4. 10.2337\/dc18-0116","journal-title":"Diabetes Care"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.06.003","article-title":"Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus","volume":"43","author":"Reach G","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017, 43:501-11. 10.1016\/j.diabet.2017.06.003","journal-title":"Diabetes Metab"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing clinical inertia in type 2 diabetes mellitus: a review","volume":"35","author":"Okemah J","year":"2018","unstructured":"Okemah J, Peng J, Qui\u00f1ones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018, 35:1735-45. 10.1007\/s12325-018-0819-5","journal-title":"Adv Ther"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01530-9","article-title":"Therapeutic inertia in the management of type 2 diabetes: a narrative review","volume":"15","author":"Rodriguez P","year":"2024","unstructured":"Rodriguez P, San Martin VT, Pantalone KM. Therapeutic inertia in the management of type 2 diabetes: a narrative review. Diabetes Ther. 2024, 15:567-83. 10.1007\/s13300-024-01530-9","journal-title":"Diabetes Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00745-5","article-title":"Clinical inertia in poorly controlled type 2 diabetes mellitus patients with obesity: an observational retrospective study","volume":"11","author":"Romera I","year":"2020","unstructured":"Romera I, D\u00edaz S, Sicras-Mainar A, L\u00f3pez-Simarro F, Dilla T, Artime E, Reviriego J. Clinical inertia in poorly controlled type 2 diabetes mellitus patients with obesity: an observational retrospective study. Diabetes Ther. 2020, 11:437-51. 10.1007\/s13300-019-00745-5","journal-title":"Diabetes Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01382-9","article-title":"Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes","volume":"14","author":"Palanca A","year":"2023","unstructured":"Palanca A, Ampudia-Blasco FJ, Calder\u00f3n JM, et al.. Real-world evaluation of GLP-1 receptor agonist therapy persistence, adherence and therapeutic inertia among obese adults with type 2 diabetes. Diabetes Ther. 2023, 14:723-36. 10.1007\/s13300-023-01382-9","journal-title":"Diabetes Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/485979-exploring-treatment-paradigms-in-type-2-diabetes-a-comparison-of-independent-and-combined-therapeutic-approaches","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:32:41Z","timestamp":1778139161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/485979-exploring-treatment-paradigms-in-type-2-diabetes-a-comparison-of-independent-and-combined-therapeutic-approaches"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":46,"URL":"https:\/\/doi.org\/10.7759\/cureus.108406","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}